Bruno Ségui

Publications

Article dans une revue (38)

The Phospholipid Bis(monoacylglycero)Phosphate Confers Antitumour Immunogenicity to Exosomes Secreted by Dendrogenin A, Which Activates Its Biosynthesis in Tumour Cells Julio Buñay,Michel Record,Philippe de Medina,Silia Ayadi,Laly Pucheuet al. Journal of Extracellular Vesicles, 2026, 15 (2), pp.e70225. ⟨10.1002/jev2.70225⟩ Article dans une revue inserm-05495718v1
TNF signature in advanced melanoma patients treated with immune checkpoint inhibitors: Results from the MELANFα clinical study Mathieu Virazels,Amélie Lusque,Stéphanie Brayer,Matthieu Genais,Carine Dufauet al. International Journal of Cancer, 2025, ⟨10.1002/ijc.35416⟩ Article dans une revue (data paper) hal-04996473v1
Ceramide metabolism alterations contribute to Tumor Necrosis Factor-induced melanoma dedifferentiation and predict resistance to immune checkpoint inhibitors in advanced melanoma patients Carine Dufau,Matthieu Genais,Elodie Mucher,Benjamin Jung,Virginie Garciaet al. Frontiers in Immunology, 2024, 15, pp.1421432. ⟨10.3389/fimmu.2024.1421432⟩ Article dans une revue inserm-04773877v1
A fluorogenic substrate for the detection of lipid amidases in intact cells Mireia Casasampere,Johnson Ung,Alejandro Iñáñez,Carine Dufau,Kazuhito Tsuboiet al. Journal of Lipid Research, 2024, 65 (3), pp.100520. ⟨10.1016/J.JLR.2024.100520⟩ Article dans une revue inserm-04873248v1
Thrombospondin-1 Silencing Improves Lymphocyte Infiltration in Tumors and Response to Anti-PD-1 in Triple-Negative Breast Cancer Elie Marcheteau,Thomas Farge,Michaël Pérès,Guillaume Labrousse,Julie Tenetet al. Cancers, 2021, 13 (16), pp.4059. ⟨10.3390/cancers13164059⟩ Article dans une revue inserm-04971585v1
Neutral Sphingomyelinase 2 Heightens Anti-Melanoma Immune Responses and Anti–PD-1 Therapy Efficacy Anne Montfort,Florie Bertrand,Julia Rochotte,Julia Gilhodes,Thomas Filleronet al. Cancer Immunology Research, 2021, 9 (5), pp.568-582. ⟨10.1158/2326-6066.CIR-20-0342⟩ Article dans une revue inserm-03402255v1
Combining TNF blockade with immune checkpoint inhibitors in patients with cancer Anne Montfort,Mathieu Virazels,Céline Colacios,Nicolas Meyer,Bruno Ségui Nature Reviews Rheumatology, 2021, 17 (9), pp.577-577. ⟨10.1038/s41584-021-00653-8⟩ Article dans une revue (article de synthèse) hal-04960542v1
New Insights into the Role of Sphingolipid Metabolism in Melanoma Lorry Carrié,Mathieu Virazels,Carine Dufau,Anne Montfort,Thierry Levadeet al. Cells, 2020, 9 (9), pp.1967. ⟨10.3390/cells9091967⟩ Article dans une revue inserm-04873888v1
Resistance of melanoma to immune checkpoint inhibitors is overcome by targeting the sphingosine kinase-1 Caroline Imbert,Anne Montfort,Marine Fraisse,Elie Marcheteau,Julia Gilhodeset al. Nature Communications, 2020, 11 (1), pp.437. ⟨10.1038/s41467-019-14218-7⟩ Article dans une revue inserm-02492179v1
Lipid metabolic Reprogramming: Role in Melanoma Progression and Therapeutic Perspectives Laurence Pellerin,Lorry Carrié,Carine Dufau,Laurence Nieto,Bruno Séguiet al. Cancers, 2020, 12 (11), pp.3147. ⟨10.3390/cancers12113147⟩ Article dans une revue inserm-04873868v1
IL13-Mediated Dectin-1 and Mannose Receptor Overexpression Promotes Macrophage Antitumor Activities through Recognition of Sialylated Tumor Cells Mohammad Alaeddine,Mélissa Prat,Verena Poinsot,Valérie Gouazé-Andersson,Hélène Authieret al. Cancer Immunology Research, 2019, 7 (2), pp.321-334. ⟨10.1158/2326-6066.CIR-18-0213⟩ Article dans une revue hal-02194445v1
Morniga-G, a T/Tn-Specific Lectin, Induces Leukemic Cell Death via Caspase and DR5 Receptor-Dependent Pathways Guillaume Poiroux,Annick Barre,Mathias Simplicien,Sandrine Pelofy,Bruno Seguiet al. International Journal of Molecular Sciences, 2019, 20 (1), pp.230. ⟨10.3390/ijms20010230⟩ Article dans une revue hal-03350717v1
Anti-TNF, a magic bullet in cancer immunotherapy? Anne Montfort,Carine Dufau,Céline Colacios,Nathalie Andrieu-Abadie,Thierry Levadeet al. Journal for Immunotherapy of Cancer, 2019, 7 (1), pp.303. ⟨10.1186/s40425-019-0802-y⟩ Article dans une revue inserm-04905685v1
The TNF Paradox in Cancer Progression and Immunotherapy Anne Montfort,Céline Colacios,Thierry Levade,Nathalie Andrieu-Abadie,Nicolas Meyeret al. Frontiers in Immunology, 2019, 10, pp.1818. ⟨10.3389/fimmu.2019.01818⟩ Article dans une revue inserm-04905614v1
Sphingomyelin Synthase 1 (SMS1) Downregulation Is Associated With Sphingolipid Reprogramming and a Worse Prognosis in Melanoma Fatima Bilal,Anne Montfort,Julia Gilhodes,Virginie Garcia,Joelle Riondet al. Frontiers in Pharmacology, 2019, 10, pp.443. ⟨10.3389/fphar.2019.00443⟩ Article dans une revue hal-02332278v1
Les anticorps anti-TNFα dans l’immunothérapie du mélanome Anne Montfort,Céline Colacios,Thierry Levade,Nathalie Andrieu-Abadie,Nicolas Meyeret al. Médecine/Sciences, 2018, 34 (10), pp.788 - 791. ⟨10.1051/medsci/2018202⟩ Article dans une revue inserm-04905584v1
TNFα blockade overcomes resistance to anti-PD-1 in experimental melanoma Florie Bertrand,Anne Montfort,Elie Marcheteau,Caroline Imbert,Julia Gilhodeset al. Nature Communications, 2017, 8 (1), pp.2256. ⟨10.1038/s41467-017-02358-7⟩ Article dans une revue inserm-04905428v1
S1P: the elixir of life for naive T cells Michaël Pérès,Anne Montfort,Nathalie Andrieu-Abadie,Céline Colacios,Bruno Ségui Cellular and molecular immunology, 2017, 15 (7), pp.657 - 659. ⟨10.1038/cmi.2017.110⟩ Article dans une revue inserm-04905494v1
TNFα blockade overcomes resistance to anti-PD-1 in experimental melanoma Florie Bertrand,Anne Montfort,Elie Marcheteau,Caroline Imbert,Julia Gilhodeset al. Nature Communications, 2017, 8 (1), ⟨10.1038/s41467-017-02358-7⟩ Article dans une revue hal-04866756v1
Downregulation of ceramide synthase-6 during epithelial-to-mesenchymal transition reduces plasma membrane fluidity and cancer cell motility Valérie Edmond,Florent Dufour,Guillaume Poiroux,Kenji Shoji,Marine Malleteret al. Oncogene, 2015, 34 (8), pp.996-1005. ⟨10.1038/onc.2014.55⟩ Article dans une revue hal-01063558v1
Chemotherapy with ceramide in TNBC Patrick Legembre,Olivier Micheau,Bruno Ségui Oncoscience, 2015, 2 (10), pp.817--818. ⟨10.18632/oncoscience.196⟩ Article dans une revue hal-01255869v1
Monogenic neurological disorders of sphingolipid metabolism Frédérique Sabourdy,Leonardo Astudillo,Céline Colacios,Patricia Dubot,Marguerite Mradet al. Biochimica et Biophysica Acta Molecular and Cell Biology of Lipids, 2015, 1851 (8), pp.1040 - 1051. ⟨10.1016/j.bbalip.2015.01.010⟩ Article dans une revue inserm-04906477v1
The Tricyclodecan-9-yl-xanthogenate D609 Triggers Ceramide Increase and Enhances FasL-Induced Caspase-Dependent and -Independent Cell Death in T Lymphocytes Delphine Milhas,Nathalie Andrieu-Abadie,Thierry Levade,Hervé Benoist,Bruno Ségui International Journal of Molecular Sciences, 2012, 13 (7), pp.8834 - 8852. ⟨10.3390/ijms13078834⟩ Article dans une revue inserm-04963209v1
Ordering of ceramide formation and caspase-9 activation in CD95L-induced Jurkat leukemia T cell apoptosis Elodie Lafont,Romain Dupont,Nathalie Andrieu-Abadie,Toshiro Okazaki,Klaus Schulze-Osthoffet al. Biochimica et Biophysica Acta Molecular and Cell Biology of Lipids, 2012, 1821 (4), pp.684-693. ⟨10.1016/j.bbalip.2012.01.012⟩ Article dans une revue inserm-04963190v1
CD95 triggers Orai1-mediated localized Ca2+ entry, regulates recruitment of protein kinase C (PKC) β2, and prevents death-inducing signaling complex formation. Nadine Khadra,Laurence Bresson-Bepoldin,Aubin Penna,Benjamin Chaigne-Delalande,Bruno Séguiet al. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108 (47), pp.19072-7. ⟨10.1073/pnas.1116946108⟩ Article dans une revue inserm-00641268v1
Targeting of T/Tn Antigens with a Plant Lectin to Kill Human Leukemia Cells by Photochemotherapy Guillaume Poiroux,Marguerite Pitié,Raphaël Culerrier,Elodie Lafont,Bruno Séguiet al. PLoS ONE, 2011, 6 (8), pp.e23315. ⟨10.1371/journal.pone.0023315⟩ Article dans une revue hal-05484992v1
Apolipoprotein E-deficient mice develop an anti-Chlamydophila pneumoniae T helper 2 response and resist vascular infection. Dani Nazzal,Nicole Therville,Houda Yacoub-Youssef,Virginie Garcia,Mogens Thomsenet al. Journal of Infectious Diseases, 2010, 202 (5), pp.782-90. ⟨10.1086/655700⟩ Article dans une revue inserm-00613672v1
Caspase-mediated inhibition of sphingomyelin synthesis is involved in FasL-triggered cell death. Elodie Lafont,Delphine Milhas,Stéphane Carpentier,Virgine Garcia,Z.-X. Jinet al. Cell Death and Differentiation, 2010, 17 (4), pp.642-54. ⟨10.1038/cdd.2009.130⟩ Article dans une revue inserm-00473914v1
Morniga G: A Plant Lectin as an Endocytic Ligand for Photosensitizer Molecule Targeting Toward Tumor‐Associated T/Tn Antigens Guillaume Poiroux,Marguerite Pitié,Raphaël Culerrier,Bruno Ségui,Els J.M. van Dammeet al. Photochemistry and Photobiology, 2010, 87 (2), pp.370-377. ⟨10.1111/j.1751-1097.2010.00858.x⟩ Article dans une revue istex hal-05485011v1
Caspase-10-dependent cell death in Fas/CD95 signalling is not abrogated by caspase inhibitor zVAD-fmk. Elodie Lafont,Delphine Milhas,Justin Teissié,Nicole Therville,Nathalie Andrieu-Abadieet al. PLoS ONE, 2010, 5 (10), pp.e13638. ⟨10.1371/journal.pone.0013638⟩ Article dans une revue inserm-00550848v1
FAN (factor associated with neutral sphingomyelinase activation), a moonlighting protein in TNF-R1 signaling. Anne Montfort,Pascal G.P. Martin,Thierry Levade,Hervé Benoist,Bruno Ségui Journal of Leukocyte Biology, 2010, 88 (5), epub ahead of print. ⟨10.1189/jlb.0410188⟩ Article dans une revue inserm-00504725v1
Two structurally identical mannose-specific jacalin-related lectins display different effects on human T lymphocyte activation and cell death. Hervé Benoist,Raphael Culerrier,Guillaume Poiroux,Bruno Ségui,Alain Jauneauet al. Journal of Leukocyte Biology, 2009, 86 (1), pp.103-14. ⟨10.1189/jlb.0708434⟩ Article dans une revue inserm-00409940v1
Interleukin-6 deficiency fails to prevent chronic rejection after aortic allografts in apolipoprotein E-deficient mice. Houda Yacoub-Youssef,Nelly Blaes,Denis Calise,Jean Claude Thiers,Nicole Thervilleet al. The Journal of Heart and Lung Transplantation, 2009, 28 (1), pp.85-92. ⟨10.1016/j.healun.2008.06.012⟩ Article dans une revue inserm-00423309v1
IL-6 deficiency attenuates murine diet-induced non-alcoholic steatohepatitis. Emmanuel Mas,Marie Danjoux,Virginie Garcia,Stéphane Carpentier,Bruno Séguiet al. PLoS ONE, 2009, 4 (11), pp.e7929. ⟨10.1371/journal.pone.0007929⟩ Article dans une revue inserm-00474274v1
FAN stimulates TNF(alpha)-induced gene expression, leukocyte recruitment, and humoral response. Anne Montfort,Bénédicte de Badts,Victorine Douin-Echinard,Pascal G.P. Martin,Jason S. Iacovoniet al. Journal of Immunology, 2009, 183 (8), pp.5369-78. ⟨10.4049/jimmunol.0803384⟩ Article dans une revue inserm-00473894v1
OPA1 cleavage depends on decreased mitochondrial ATP level and bivalent metals. Laurent Baricault,Bruno Ségui,Laurie Guégand,Aurélien Olichon,Annie Valetteet al. Experimental Cell Research, 2007, 313 (17), pp.3800-8. ⟨10.1016/j.yexcr.2007.08.008⟩ Article dans une revue inserm-00174981v1
Cleavage and cytoplasmic relocalization of histone deacetylase 3 are important for apoptosis progression. Fabrice Escaffit,Olivier Vaute,Martine Chevillard-Briet,Bruno Segui,Yasunari Takamiet al. Molecular and Cellular Biology, 2007, 27 (2), pp.554-67. ⟨10.1128/MCB.00869-06⟩ Article dans une revue hal-00317862v1
Lysosomal sphingomyelinase is not solicited for apoptosis signaling Christine Bezombes,Bruno Ségui,Olivier Cuvillier,Alain Bruno,Emmanuelle Uro-Costeet al. FASEB Journal, 2000, 15 (2), pp.297-299. ⟨10.1096/fj.00-0466fje⟩ Article dans une revue inserm-04826847v1

Poster de conférence (7)

Evaluation of the biodistribution of different anti-TNF agents in combination with Immunotherapy in Melanoma model using ImmunoTEP Céline Colacios,Laure Badier,Carine Pestourie,Bruno Ségui,Isabelle Quelven Toulouse Onco Week (TOW) Symposium, Feb 2025, Toulouse, France. Poster de conférence inserm-04973597v1
Preclinical and patient transcriptomics RNA-seq highlight the impact of TNF blockade on the inflammatory status of melanoma tumours. Matthieu Genais,Mathieu Virazels,Anne Montfort,Vera Pancaldi,Bruno Ségui EACR conferences: Defence is the Best Attack: Immuno-Oncology Breakthroughs, May 2023, Barcelona (ES), Spain Poster de conférence hal-04991620v1
TNF plasma levels in advanced melanoma patients treated with immune checkpoint inhibitors: results from the MELANFα clinical study. Mathieu Virazels,Amélie Lusque,Thomas Filleron,Clara-Maria Scarlata,Maha Ayyoubet al. Defence is the Best Attack: Immuno-Oncology Breakthroughs, May 2023, Barcelona, France Poster de conférence hal-04971045v1
Triple combination of ipilimumab + nivolumab + anti-TNF in treatment naive melanoma patients: Final analysis of TICIMEL, a phase Ib prospective clinical trial Bruno Ségui,Nicolas Meyer,Amélie Lusque,Mathieu Virazels,Thomas Filleronet al. ESMO congress 2022, Sep 2022, Paris, France. Annals of Oncology, 33 (suppl_7), pp.S936-S937, 2022, ⟨10.1016/j.annonc.2022.07.972⟩ Poster de conférence hal-04975541v1
TNF plasma levels in advanced melanoma patients treated with immune checkpoint inhibitors: results from the MELANFα clinical study. Mathieu Virazels,Anne Montfort,Amélie Lusque,Thomas Filleron,Céline Colacioset al. ESMO Congress 2022, Sep 2022, Paris, France Poster de conférence hal-04971055v1
Combining TNF blockade with immune checkpoint inhibitors in advanced melanoma patients Mathieu Virazels,Anne Montfort,Thomas Filleron,Carine Dufau,Maha Ayyoubet al. 53rd congress of the French Society of Immunology, Dec 2021, Paris, France Poster de conférence hal-04970987v1
Neutral sphingomyelinase 2 heightens anti-melanoma immune response and synergizes with immune checkpoint inhibitors. Anne Montfort,Florie Bertrand,Julia Rochotte,Nathalie Andrieu-Abadie,Thierry Levadeet al. 52ème Congrès de la Société Française d'immunologie (SFI), Nov 2019, Nantes, France Poster de conférence hal-04970950v1

Communication dans un congrès (21)

Anti-TNF in melanoma immunotherapy: from basic research to early clinical trials in advanced melanoma patients Bruno Ségui Summer school on Medicines, Vitor Faça, Jun 2024, Ribeirão Preto, Brazil Communication dans un congrès hal-04991577v1
Targeting ceramide metabolism in melanoma to improve the efficacy of immune checkpoint inhibitor therapy: from basic mechanisms to the clinic. Bruno Ségui,Carine Dufau,Benjamin Jung,Matthieu Genais,Thierry Levadeet al. XV SPHINGOLIPID CLUB MEETING, Sep 2024, Erlangen-Nürnberg, Germany Communication dans un congrès hal-04974692v1
Anti-TNF in melanoma therapy: from basic research to early clinical trials in advanced melanoma patients. Bruno Ségui Summer School on Medicines, Marçal Pastor-Anglada, Jul 2023, Barcelona (ES), Spain Communication dans un congrès hal-04991531v1
Triple combination of anti-CTLA-4, anti-PD-1 and anti-TNF in mouse melanoma models and advanced melanoma patients. Bruno Ségui,Anne Montfort,Mathieu Virazels,Matthieu Genais,Amélie Lusqueet al. EACR conferences “Defence is the Best Attack: Immuno-Oncology Breakthroughs”, Joan Seoane, May 2023, Barcelona, Spain Communication dans un congrès hal-04974544v1
Ceramide metabolism alterations contribute to Tumor Necrosis Factor-induced melanoma dedifferentiation. Bruno Ségui,Carine Dufau,Matthieu Genais,Elodie Mucher,Benjamin Junget al. International Ceramide Conference, Apr 2023, Charleston, South Carolina, United States Communication dans un congrès hal-04974508v1
Ceramide metabolism alterations contribute to Tumor Necrosis Factor-induced melanoma dedifferentiation: from basic research to immunotherapy in advanced melanoma patients. Bruno Ségui,Carine Dufau,Matthieu Genais,Elodie Mucher,Benjamin Junget al. FEBS Sphingolipid biology, Oct 2023, Funchal (Madeira Island), Portugal Communication dans un congrès hal-04974669v1
Ceramide metabolism in melanoma: from basic mechanisms to immunotherapy in advanced melanoma patients. Bruno Ségui ESMED general assembly, Aug 2022, Madrid (Online Only), Spain Communication dans un congrès hal-04974455v1
Anti-TNF in melanoma immunotherapy: from basic findings to the clinic. Bruno Ségui 10èmes Journée d’Immunologie et Immunothérapie des Cancers (JIIC), Ali Bettaieb, Dec 2022, Dijon, France Communication dans un congrès hal-04974429v1
Early phase clinical trial in melanoma: a repositioning venture Bruno Ségui The 12th Summer School on Medicines, Pierre Cordelier, Jul 2022, Toulouse, France Communication dans un congrès hal-04975301v1
Anti-TNF in melanoma immunotherapy: from basic findings to the clinic Bruno Ségui Melanoma Workshop 2021, C. BERTOLOTTO and R. BALLOTTI, Aug 2021, Nice, France Communication dans un congrès hal-04974420v1
Anti-TNF + Nivolumab + Ipilimumab pour le traitement du mélanome avancé : premiers résultats de l’essai clinique TICIMEL Anne Montfort,Thomas Filleron,Mathieu Virazels,Bruno Ségui,Nicolas Meyer Journées dermatologiques de Paris, Nov 2021, Paris, France Communication dans un congrès hal-04970832v1
Neutral sphingomyelinase 2 heightens anti-melanoma immune responses and anti-PD-1 therapy efficacy. Bruno Ségui The 141st Annual Meeting of the Pharmaceutical Society of Japan, Pharmaceutical Society of Japan, Mar 2021, Hiroshima (Virtual meeting), Japan Communication dans un congrès hal-04974402v1
Combining TNF inhibitors to anti-PD-1 and anti-CTLA-4 for the treatment of advanced melanoma patients Anne Montfort,Mathieu Virazels,Carine Dufau,Stéphanie Brayer,Nathalie Andrieu-Abadieet al. 17ème journées du Cancéropôle Grand Sud-Ouest, Nov 2021, Carcassone, France Communication dans un congrès hal-04970934v1
Ceramide metabolism in melanoma: From basic mechanisms to Immunotherapy in advanced melanoma patients. Bruno Ségui Introduction lecture at the 14th Sphingo Therapy Conference, Toshiro Okazaki, Jan 2020, Kanazawa, Japan Communication dans un congrès hal-04974371v1
Neutral sphingomyelinase 2 heightens anti-melanoma immune response and synergizes with anti-PD-1. Anne Montfort,Florie Bertrand,Julia Rochotte,Nathalie Andrieu-Abadie,Thierry Levadeet al. Toulouse Oncoweek, Feb 2020, Toulouse, France Communication dans un congrès hal-04971026v1
Resistance of Melanoma to Immune Checkpoint Inhibitors is Overcome by Targeting the Sphingosine Kinase 1 Céline Colacios,Caroline Imbert,Anne Montfort,Marine Fraisse,Elie Marcheteauet al. Canceropole GSO, Canceropole GSO, Nov 2019, Arcachon, France Communication dans un congrès hal-04993281v1
Targeting TNF-alpha to overcome resistance to immunotherapy in melanoma Bruno Ségui 11th Summer School on Medicines, Denis Deblois, Jun 2019, Montreal, Canada Communication dans un congrès hal-04974731v1
TNF-dependent mechanisms of immune escape and resistance to immunotherapy Bruno Ségui 3rd European R&D Day in immuno-oncology, Mar 2019, Amsterdam, Netherlands Communication dans un congrès hal-04974781v1
Ceramide metabolism in melanoma: from basic mechanisms to immunotherapy in advanced melanoma patients. Bruno Ségui,Anne Montfort,Caroline Imbert,Céline Colacios,Nathalie Andrieu-Abadieet al. FEBS 2019 Sphingolipid Biology: Sphingolipids in Physiology and Pathology, Giovanni D'Angelo, Christopher J. Clarke, Liana C. Silva, May 2019, Cascais, Portugal Communication dans un congrès hal-04974329v1
Anti-TNF in melanoma immunotherapy: from basic findings to the clinic Bruno Ségui 9ème Journée d’Immunologie et Immunothérapie des Cancers (JIIC), Dec 2019, Dijon, France Communication dans un congrès hal-04974761v1
Combining TNF-targeting antibodies to immune checkpoint inhibitors in melanoma Anne Montfort,Florie Bertrand,Elie Marcheteau,Caroline Imbert,Julia Gilhodeset al. Toulouse Oncoweek, Feb 2018, Toulouse, France Communication dans un congrès hal-04970883v1

Thèse (2)

Impact of TNF on ceramide metabolism and on the inflammatory and differentiation status of melanoma : from basic mechanisms to the clinic and back Bruno Ségui,Matthieu Genais,Vera Pancaldi Life Sciences [q-bio]. Université Paul Sabatier - Toulouse III, 2023. English. ⟨NNT : 2023TOU30348⟩ Thèse tel-05002536v1
Rôle du métabolisme du céramide dans la dédifférenciation du mélanome induite par le TNF Nathalie Andrieu-Abadie,Carine Dufau,Bruno Ségui Biologie cellulaire. Université toulouse 3 Paul Sabatier, 2022. Français. ⟨NNT : ⟩ Thèse tel-04967074v1

Brevet (4)

Inhibitors of the ceramide metabolic pathway for overcoming immunotherapy resistance in cancer. Nathalie Andrieu-Abadie,Nicolas Meyer,Bruno Ségui,Carine Dufau,Thierry Levadeet al. France, Patent n° : WO2024052356A1. 2022 Brevet inserm-04976432v1
Use of SK2 inhibitors in combination with immune checkpoint blockade therapy for the treatment of cancer. Nathalie Andrieu-Abadie,Bruno Ségui,Thierry Levade,Alexandre Ghenassia France, Patent n° : WO2020208060A1. 2020 Brevet inserm-04976354v1
Methods for predicting the survival of patients suffering from melanoma. Nathalie Andrieu-Abadie,Nicolas Meyer,Bruno Ségui,Celine Colacios,Joëlle Riondet al. France, Patent n° : WO2020193746A1. 2019 Brevet inserm-04976387v1
Use of sk1 as biomarker for predicting response to immune checkpoint inhibitors. Nathalie Andrieu-Abadie,Nicolas Meyer,Bruno Ségui,Celine Colacios,Thierry Levadeet al. France, Patent n° : WO2019162325A1. 2019 Brevet inserm-04976375v1